The impact of the policy on businesses and users

Enterprises: Policies provide a solid backing for corporate innovation and development. The special review process for innovative medical devices has significantly shortened the approval cycle for high-end endoscopes, enabling enterprises to bring their R&D achievements to market more quickly—for instance, Weitong’s intelligent-focus endoscope has been rapidly approved and launched. Meanwhile, the establishment of standardized technical organizations and the dynamic adjustment of product categories have set clear boundaries for enterprise R&D, reducing itsBlindness. At the same time, centralized procurement and medical insurance policies are driving enterprises toward transformation. Under the DRG/DIP payment reform, medical institutions increasingly favor cost-effective equipment, prompting enterprises to shift from simply selling equipment to an integrated model that includes “equipment + consumables + services.” Moreover, preferential procurement policies aimed at grassroots-level facilities are guiding enterprises to develop simplified endoscopic products tailored specifically for primary care settings. Additionally, enhanced post-market surveillance requirements are prompting enterprises to increase their investments in quality testing and adverse event tracing, thereby raising compliance costs.

For medical institutions, the policy has accelerated the adoption of high-end medical equipment. In particular, primary-level medical institutions can take advantage of favorable policies to procure high-quality, domestically produced endoscopes at lower prices, thereby enhancing their diagnostic and treatment capabilities at the grassroots level. Moreover, clearly defined technical review standards have reduced the compliance risks associated with equipment procurement for medical institutions. For patients, the policy-driven substitution of imported products with domestically manufactured alternatives has made endoscopic examinations and treatments more affordable. After certain endoscopic products were included in centralized procurement, patients’ medical expenses have been significantly reduced. At the same time, strengthened regulatory oversight has ensured product quality, minimizing the risk of equipment malfunctions during patient use and further enhancing the safety of medical care.